BECOME A MEMBER
Connect with healthcare professionals around the globe to get the most up-to-date medical cannabis information.
Get Involved
TAKE OUR COURSES
The curriculum brings hands-on practical guidance on how to develop personalized treatment regimens and more.
The effectiveness of self-directed medical cannabis treatment for pain.
Authors: Xiaoxue Li, Jacob M.Vigil, Sarah S. Stith, Franco Brockelman, Keenan Keeling, Branden Hall
Complementary Therapies in Medicine, October 2019
—
The prior medical literature offers little guidance as to how pain relief and side effect manifestation may vary across commonly used and commercially available cannabis product types. We used the largest dataset in the United States of real-time responses to and side effect r…
A History of the US Medical Cannabis Movement and Its Importance to Pediatricians
SCC member Kevin M. Takakuwa, MD outlines on the historical impact of cannabis and its relevance to pediatric practice. The article highlights how cannabis may benefit seizure disorders in children and young adults.
Cannabis and Pain.
Authors: Ethan B. Russo
Pain Medicine, 16 September 2019
—
This editorial is occasioned by the publication in Pain Medicine of two quite distinct articles [1,2] on the topical subject of cannabis and pain. As a point of departure, it is necessary to define terms. Cannabis sativa L. is a highly variable biochemical and morphological pl…
Immune Responses Regulated by Cannabidiol.
Authors: James M. Nichols and Barbara L.F. Kaplan
Cannabis and Cannabinoid Research, 4 September 2019
—
Introduction: Cannabidiol (CBD) as Epidiolex® (GW Pharmaceuticals) was recently approved by the U.S. Food and Drug Administration (FDA) to treat rare forms of epilepsy in patients 2 years of age and older. Together with the increased societal acceptance of recreational cannabi…
Cannabinoid hyperemesis syndrome: a review of the literature.
Authors: Eleonore Deceuninck, Denis Jacques
Psychiatria Danubina, September 2019
—
BACKGROUND: Cannabinoid Hyperemesis Syndrome (CHS) is characterized by cyclic vomiting and compulsive need to take hot showers in the context of chronic cannabis use. Physicians’ lack of knowledge of CHS often results in a diagnostic delay of several years. The purpose of this…
Medical Use of Cannabis in 2019.
Authors: Kevin P. Hill
JAMA, 9 August 2019
—
Nearly 10% of cannabis users in the United States report using it for medicinal purposes.1 As of August 2019, 33 states and the District of Columbia have initiated policies allowing the use of cannabis or cannabinoids for the management of specific medical conditions. Yet, the…
Benefit of Tetrahydrocannabinol versus Cannabidiol for Common Palliative Care Symptoms.
Authors: David J. Casarett, Jessica N. Beliveau, and Michelle S. Arbus
Journal of Palliative Medicine, 6 August 2019
—
Objectives: To determine the relative contributions of tetrahydrocannabinol (THC) and cannabidiol (CBD) to patients’ self-ratings of efficacy for common palliative care symptoms. Design: This is an electronic record-based retrospective cohort study. Model development used logi…
Opportunities for cannabis in supportive care in cancer.
Authors: Amber S. Kleckner, Ian R. Kleckner, Charles S. Kamen, Mohamedtaki A. Tejani, et al
Therapeutic Advances in Medical Oncology, 1 August 2019
—
Cannabis has the potential to modulate some of the most common and debilitating symptoms of cancer and its treatments, including nausea and vomiting, loss of appetite, and pain. However, the dearth of scientific evidence for the effectiveness of cannabis in treating these symp…
Association between cannabis use and complications related to ulcerative colitis in hospitalized patients: A propensity matched retrospective cohort study.
Authors: Chimezie Mbachi, Bashar Attar, Olamide Oyenubi, Wang Yuchen, Aisien Efesomwan, et al
Medicine, August 2019
—
Ulcerative colitis (UC) is a chronic inflammatory process that is occasionally associated with complications that cause significant morbidity and mortality. Studies in experimental animal models have demonstrated a beneficial effect of cannabis on intestinal inflammation. It i…
Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use.
Authors: Joshua D. Brown, Almut G. Winterstein
Journal of Clinical Medicine, 8 July 2019
—
Cannabidiol (CBD) is ubiquitous in state-based medical cannabis programs and consumer products for complementary health or recreational use. CBD has intrinsic pharmacologic effects and associated adverse drug events (ADEs) along with the potential for pharmacokinetic and pharm…
A Not-So-Proud Memory
During Pride Month, we owe it to history to recall an embarrassing, tragic twist in the relationship between AIDS activism and the medical marijuana movement.
How the Aids Epidemic Catalyzed the Medical Marijuana Movement
The historical account of Dennis Peron, the medical cannabis and human rights activist who was instrumental in bringing attention to AIDS and changing cannabis policy in California.